Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-08

Study Completion Date

2025-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to assess the safety and tolerability of NMNH as a dietary supplement for human consumption. The current study aims to comprehensively evaluate its potential effects on pharmacokinetics, physical performance, biological age and overall quality of life. These findings will expand our understanding of NMNH therapeutic potential and guide its future clinical applications in anti-aging interventions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days

NCT00964340

Atrophy, Muscular

COMPLETED PHASE1

Lipoic Acid as a Treatment for Acute Optic Neuritis

NCT01294176

Optic Neuritis

COMPLETED PHASE1

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546

Healthy

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

NCT04539041

Progressive Supranuclear Palsy (PSP)

COMPLETED PHASE1

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

NCT06940336

Transthyretin Amyloid Polyneuropathy

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 80 healthy adult participants were considered for enrolment in the study based on predefined eligibility criteria and screening assessments, which included demographics, medical history, clinical laboratory tests, diagnostic evaluations, and prior medication review.

The 80 participants were randomly assigned to placebo group, NMNH 125 mg group, NMNH 250 mg group, or NMNH 500 mg group, and oral supplementation for 90 consecutive days.

Baseline assessments comprised NAD+ levels, BMI, biological age evaluation, a six-minute walking test, and a quality-of-life assessment. These parameters were also evaluated during Day 45 and day 90 . Participants were formally enrolled in the study after reconfirmation of eligibility.

Blood samples were collected at multiple time points (0h, 0.5h, 1h, 2h, 4h, 6h, 12h, and 24h) after the first dose of supplementation to assess NAD+ levels. Pharmacokinetic parameter assessments were conducted exclusively for the second set of 10 participants in each group who provided informed consent.

Throughout the study, physical examinations, vital signs, concomitant medications, and adverse events were recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multi-center, Double-blind, Placebo-controlled, Randomized, Multiple-arm, Parallel Study

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Ingredient: Starch Dosage form: Capsule, 125mg/capsule Frequency: 2 capsules per day Duration: 90 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Starch powder

Group 2

Ingredient: NMNH Dosage form: Capsule, 62.5 mg/capsule Frequency: 2 capsules per day Duration: 90 days

Group Type EXPERIMENTAL

NMNH

Intervention Type OTHER

Reduced Nicotinamide Mononucleotide

Group 3

Ingredient: NMNH Dosage form: Capsule, 125 mg/capsule Frequency: 2 capsules per day Duration: 90 days

Group Type EXPERIMENTAL

NMNH

Intervention Type OTHER

Reduced Nicotinamide Mononucleotide

Group 4

Ingredient: NMNH Dosage form: Capsule, 250 mg/capsule Frequency: 2 capsules per day Duration: 90 days

Group Type EXPERIMENTAL

NMNH

Intervention Type OTHER

Reduced Nicotinamide Mononucleotide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NMNH

Reduced Nicotinamide Mononucleotide

Intervention Type OTHER

Placebo

Starch powder

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult healthy male/females aged 40 to 65 years.
2. Participants with Body Mass Index (BMI) between 18.5 and 35 kg/m2.
3. Participants who are willing to provide written Informed Consent for participating in the study
4. Participants who are able to follow verbal and written study directions.
5. Participants must be able to maintain consistent diet and lifestyle habits throughout the study.
6. Participants must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study.
7. Participants willing to administer assigned dietary supplements for 3 months.

Exclusion Criteria

1. Participants on current use of prescription or over-the-counter nicotinic acid.
2. Participants using any statin drugs.
3. Participants having used any tobacco product or used a recreational drug in the past 6 months.
4. Participants having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator.
5. Participants with documented presence of atherosclerotic disease and/or cardiopulmonary disease.
6. Participants with history of drug or alcohol abuse.
7. Participants with history of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participant's ability to comply with study requirements.
8. Participants unwilling to discontinue use of conventional multivitamin/mineral or other supplements at least two weeks prior to the start of study.
9. Participants who are currently participating in or planning to begin a weight loss diet during the study period.
10. Participants who chronically use over-the-counter medication which would interfere with study endpoints.
11. Participants whose lifestyle or schedule incompatible with the study protocol.
12. Participants with known hypersensitivity to the drug components used during the study.
13. Female participants with positive result for urinary beta human chorionic gonadotropin or gestation period or breastfeeding.
14. Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.
15. Currently, or within the past 30 days, enrolled in a different clinical investigation.
16. Inability to provide a venous blood sample.
17. Unable or unwilling to provide written informed consent for participation in study.
18. Patients with a current diagnosis of any form of cancer within the past 5 years, regardless of disease stage or treatment status, are ineligible for participation in this clinical trial. Any history of cancer within this timeframe must be documented and confirmed through medical records or pathology reports.

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes